VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a $500,000 ...
Reported ~25% YoY revenue growth in H1 FY27, reflecting continued business momentum as the it remains focused on timely project execution, efficient resou ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results